Evolution of HER2-Positive Mammary Carcinoma: HER2 Loss Reveals Claudin-Low Traits in Cancer Progression

Researchers studied cell lines derived from two transgenic mammary tumors driven by human HER2 that showed different dynamics of HER2 status. A dynamic model of HER2 status could lead to the identification of new druggable targets to counteract the resistance to HER2-targeted therapy caused by HER2 loss.